MicroPort CRM announced that it received expanded labeling for its range of implantable pacemakers — Alizea, Borea and Celea. Shanghai, China–based MicroPort’s pacemakers received expanded labeling for left bundle branch area pacing (LBBAP). The company says LBBAP, which utilizes the heart’s natural conduction system efficiency, is seen as the new approach to physiological pacing. MicroPort […]
MicroPort Scientific
FDA approves next-gen MicroPort CRM pacemakers
MicroPort CRM announced today that it received FDA approval for its Alizea and Celea implantable pacemakers. The cardiac rhythm management subsidiary of MicroPort Scientific said its newly approved devices are the longest-lasting pacemakers for their size on the market today. They offer a volume of just 11cc and a projected longevity of 13 years. Additionally, […]
Robocath, MicroPort enter JV
Robocath announced today that it created a joint venture with MicroPort Scientific through its MicroPort MedBot subsidiary. Rouen, France-based Robocath said in a news release that the partnership is designed to enable the commercialization of its R-One robotic-assisted platform in China, as MedBot is based in Shanghai. Both companies are set to engage in research […]
Stent makers point to quality-of-life findings by massive federal study
The giant federal study that found the use of stents in stable heart-disease patients is no better than drugs to treat clogged arteries reached another, less-hyped conclusion. Manufacturers of stents for percutaneous coronary intervention (PCI) note that the Ischemia study also concluded that patients who undergo a stenting procedure have a better quality of life. They suffer […]
Study: Stents no better than drugs for stable heart disease
This article has been updated with stock market results and comments from Medtronic. A major new study has concluded that the use of stents in stable heart disease patients is no better than drugs to treat clogged arteries. Results of the Ischemia study were released at the American Heart Association annual meeting in Philadelphia on Saturday. The […]
MicroPort Scientific joins $20m Series C for Rapid Medical
MicroPort Scientific has joined a $20 million Series C round for neurovascular device maker Rapid Medical. Israel-based Rapid Medical said that proceeds from the now closed Series C round will be used to support the completion of its TIGER U.S. IDE study and further commercial growth of its minimally invasive stroke treatment and prevention devices. The […]
MicroPort’s drug-eluting stent performs well in European study
MicroPort Scientific’s Firehawk rapamycin target eluting coronary stent performed comparably to Abbott’s Xience stent family in a study just published in The Lancet. The TARGET AC multi-center, randomized controlled trial enrolled 1,653 patients at 21 clinical study sites in Europe. Firehawk met the trial’s non-inferiority primary endpoint of target lesion failure rate at 12 months of 6.1% versus 5.9% for the […]
LivaNova closes $190 CRM sale to MicroPort
LivaNova (NSDQ:LIVN) said today that it closed the $190 million sale of its cardiac rhythm management business to China’s MicroPort Scientific (HK:00853). The companies are already partners in a CRM join venture in the People’s Republic. LivaNova, formed by the $2.7 billion merger of Italy’s Sorin and Cyberonics in October 2015, said in September that it was putting the CRM business on the auction […]
MicroPort Scientific buys Lombard Medical out of bankruptcy
Lombard Medical Technologies (NSDQ:EVAR) said today that it was acquired out of bankruptcy by MicroPort Scientific (HK:00853), which hopes to get Lombard’s stent grafts on the market in China. MicroPort put $15 million into Lombard back in December 2016 in a deal that aimed to accelerate the commercialization of Lombard’s Aorfix and Altura stent grafts for treating abdominal […]
LivaNova finalizes details in $190m CRM sale to MicroPort
LivaNova (NSDQ:LIVN) said today it finalized the details in a deal to sell its cardiac rhythm management business to China’s MicroPort Scientific (HK:00853) in a deal worth $190 million. The companies, which are already partners in a CRM joint venture in the People’s Republic, originally announced the deal last November. London-based LivaNova said that its announcement follows “successful […]
LivaNova to deal CRM biz to MicroPort for $190m
LivaNova (NSDQ:LIVN) said today that it inked a deal to sell its cardiac rhythm management business to China’s MicroPort Scientific (HK:00853) for $190 million in cash. The companies, which are already partners in a CRM join venture in the People’s Republic, said the sale for LivaNova’s 900-worker CRM business is slated to close during the second quarter […]